Elena Nikulina

Ocugen targets inherited retinal diseases with new gene therapy approach

Ocugen targets inherited retinal diseases with new gene therapy approach
Ocugen debuts gene therapy platform

Ocugen, Inc. has introduced its latest modifier gene therapy platform aimed at treating inherited retinal and blindness diseases, presenting the technology at three major conferences this month.

The company’s participation underscores a growing interest in next-generation therapies for vision loss. Ocugen’s innovation focuses on genetic conditions with significant unmet needs, positioning the company at the forefront of ophthalmic research. Investors and industry stakeholders continue to monitor developments, given the potential impact on future treatment paradigms.

Ocugen is also pursuing gene therapies for inherited retinal conditions, including early-stage development for Stargardt disease, which affects an estimated 100,000 patients without FDA approved treatment options (read more). The company recently completed trial enrollment for its OCU400 and OCU410ST programs. Ocugen projects its cash runway will extend into 2028 following positive OCU410 data (details here).

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.